

M&G invests in pioneering cancer screening and detection biotechnology company Harbinger Health

- *The company's goal is to lead the way to a future where cancer screening is routine, affordable and accessible to everyone*

London, 29 September 2023 – M&G Investments today announces it has invested in Harbinger Health (“Harbinger”), a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection. The US based company has raised \$140 million in Series B funding to complete the clinical validation of the firm’s first blood-based cancer screening product and scale-up ahead of its first product launch.

The company’s goal is to lead the way to a future where cancer screening is routine, affordable and accessible to everyone, and is expected to launch its first product – a laboratory developed test (LDT) for the detection of early cancer – in 2025. Harbinger’s product development strategy is designed to enable low-cost population testing to achieve broad affordability, improve Positive Predictive Value (PPV) to reduce the burden of false positives, and quantitative individual longitudinal monitoring to better guide clinical decision making if cancer is detected. Harbinger’s platform, HarbingerHx, leverages machine learning, proprietary insights into the molecular biology of cancer’s origins, and growing datasets to develop insights that maximise clinical informativeness.

M&G was one of a number of investors in the company’s latest financing round. M&G’s investment was made by Catalyst, the firm’s £5 billion purpose-led flexible private assets strategy, which invests in innovative solutions to some of the world’s biggest environmental and social challenges, on behalf of the £129 billion Prudential With-Profits Fund, which includes the £53.5 billion PruFund.

Niranjan Sirdeshpande, Head of Catalyst Investment, M&G, comments: “Innovation in medical science is being led by companies such as Harbinger, whose technology has the potential to change how we screen, detect and treat cancer in the future. By providing patient capital over the long-term, we are investing in companies that are scaling-up, to bring transformational products such as this to the market which stand to benefit our societies as a whole.”

Stephen Hahn, M.D., CEO of Harbinger Health, says: “At Harbinger, our goal is to lead the way to a future where cancer screening is routine, affordable and accessible for everyone. We have a unique opportunity to make cancer screening tools work better and work for more people through our biological and technical solutions. We are achieving this by combining machine learning with insights into the biology of cancer’s origins and individual risk in order to provide actionable information to providers, enabling them

to guide improved clinical decision making for their patients. This is where I see our greatest potential to reduce cancer mortality rates in our lifetimes.”

-ENDS-

Notes to Editors

The Catalyst investment strategy sits within M&G's £74 billion Private Markets business. With over two decades of experience in investing in private credit, private equity, real estate, infrastructure and structured credit on behalf of Prudential policyholders and external clients.

Drawing on this expertise and track record in private markets, Catalyst is a global, flexible strategy investing in companies with innovative solutions to some of the world's biggest environmental and social challenges.

If you require any further information, please contact:

M&G Investments

Corporate Communications
Irene Chambers
irene.chambers@mandg.co.uk
+44 (0)7825 696815

About M&G Investments

M&G Investments is part of M&G plc, a savings and investment business which was formed in 2017 through the merger of Prudential plc's UK and Europe savings and insurance operation and M&G, its wholly owned international investment manager. M&G plc listed as an independent company on the London Stock Exchange in October 2019 and has over £332 billion of assets under management (as at 30 June 2023). M&G plc has customers in the UK, Europe, the Americas and Asia, including individual savers and investors, life insurance policy holders and pension scheme members.

For nearly nine decades M&G Investments has been helping its customers to prosper by putting investments to work, which in turn creates jobs, homes and vital infrastructure in the real economy. Its investment solutions span equities, fixed income, multi asset, cash, private debt, infrastructure and real estate.

M&G recognises the importance of responsible investing and is a signatory to the United Nations Principles for Responsible Investment (UNPRI) and is a member of the Climate Bonds Initiative Partners Programme.

M&G plc has committed to achieve net zero carbon emissions on its total book of assets under management and administration by 2050 and committed to reduce operational carbon emissions as a corporate entity to net zero by 2030.

For more information, please visit: <https://global.mandg.com/>

Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing low-cost, multi-cancer blood tests. Harbinger envisions a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies. Harbinger was founded by Flagship Pioneering after three years of foundational research in its Labs unit and launched in 2020. Learn more about Harbinger by visiting www.harbinger-health.com or following us on Twitter (@harbingerhlth) and LinkedIn.

Media Contact
press@harbinger-health.com

This press release reflects the authors' present opinions reflecting current market conditions; are subject to change without notice; and involve a number of assumptions which may not prove valid. It has been written for informational purposes only and should not be considered as investment advice or as a recommendation of any particular security, strategy or investment product.

Past performance is not a guide to future performance. The services and products herein are available only to investment professionals and are not available to individual investors, who should not rely on this communication. Information given in this document has been obtained from, or based upon, sources believed by us to be reliable and accurate although M&G does not accept liability for the accuracy of the contents.

This financial promotion is issued by M&G Luxembourg S.A. in the EEA, registered office 16, boulevard Royal, L-2449, Luxembourg and M&G Investment Management Limited in the UK and outside the EEA (unless stated otherwise), registered in England and Wales under numbers 936683 with its registered office at 10 Fenchurch Avenue, London EC3M 5AG. M&G Investment Management Limited is authorised and regulated by the Financial Conduct Authority. The registered office of M&G Luxembourg S.A. is 16, boulevard Royal, L-2449, Luxembourg. M&G Luxembourg S.A. may terminate arrangements for marketing under the new Cross-Border Distribution Directive denotification process.